RA-backed PepGen sets terms for upcoming IPO; Sanofi commences dosing of Denali candidate in ALS
Though the market has experienced a strong downturn this year, a precarious few companies are testing the IPO waters. And PepGen is the newest biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.